by: Elizabeth Balboa, Benzinga Staff Writer
The drugstore operator reached out to representatives weeks ago to initiate discussions, and no offer has yet been extended. At time of the first reports, AmerisourceBergen, one of the largest drug distributors in the U.S., was valued at $19.6 billion.
Why It's Important
The vertical integration would secure Walgreens an in-house supplier of retail pharmacy goods as well as a specialty-drug distribution business working directly with physicians and clinics. The assets would well supplement Walgreens’ pharmaceutical-wholesale business, which distributes products to doctors, hospitals and pharmacies globally.
Walgreens would also acquire AmerisourceBergen’s patient-services sites facilitating insurance reimbursements and counseling on health care cost reductions.
The purchase would limit costs in the drug supply chain, increase appeal with pharmacy benefit managers and insurers and strengthen it against rivals like Amazon.com, Inc. AMZN 1.17%, according to CNBC.
The two already enjoy a close relationship, with Walgreens represented on AmerisourceBergen’s board and ranking as the firm’s largest client. Walgreens represented 30 percent of AmerisourceBergen’s $153.1 billion revenue last year.
The two are also five years into a 13-year agreement for AmerisourceBergen to buy generic drugs through a Walgreens group purchasing organization and to be the drugstore’s primary pharmaceuticals distributor.
AmerisourceBergen was up more than 13 percent at $101.4 in pre-market trading. CVS and Aetna were trading down marginally.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.